Treatment of chronic hemodialysis patients with low-dose fenofibrate effectively reduces plasma lipids and affects plasma redox status.

Lipids in Health and Disease
Agnieszka MakówkaMichał Nowicki

Abstract

Dyslipidemia is common in chronic hemodialysis patients and its underlying mechanism is complex. Hemodialysis causes an imbalance between antioxidants and production of reactive oxygen species, which induces the oxidative stress and thereby may lead to accelerated atherosclerosis. Statins have been found to be little effective in end-stage kidney disease and other lipid-lowering therapies have been only scarcely studied. The study aimed to assess the effect of low-dose fenofibrate therapy on plasma lipids and redox status in long-term hemodialysis patients with mild hypertriglyceridemia.Twenty seven chronic hemodialysis patients without any lipid-lowering therapy were included in a double-blind crossover, placebo-controlled study. The patients were randomized into two groups and were given a sequence of either 100 mg of fenofibrate per each hemodialysis day for 4 weeks or placebo with a week-long wash-out period between treatment periods. Plasma lipids, high sensitive C-reactive protein (CRP), urea, creatinine, electrolytes, phosphocreatine kinase (CK), GOT, GPT and plasma thiols (total and free glutathione, homocysteine, cysteine and cysteinylglycine) were measured at baseline and after each of the study periods. Plasma aminot...Continue Reading

References

Aug 1, 1977·Metabolism: Clinical and Experimental·J D BrunzellD J Sherrard
Oct 4, 1995·JAMA : the Journal of the American Medical Association·C J BousheyA G Motulsky
Jun 11, 1997·JAMA : the Journal of the American Medical Association·I M GrahamG Andria
Nov 20, 1998·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·B L Kasiske
Jun 11, 1999·Journal of the American Society of Nephrology : JASN·M E SulimanJ Bergström
Mar 20, 2001·The Journal of Clinical Investigation·M A HofmannA M Schmidt
Feb 19, 2002·Kidney International·Jonathan HimmelfarbEllen McMonagle
Mar 9, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Jean-Claude AnsquerUNKNOWN DAIS Investigators
Mar 15, 2005·Scandinavian Journal of Urology and Nephrology·Qiang YaoPeter Stenvinkel
Aug 26, 2006·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Matthew A RobertsFrancesco L Ierino
Sep 19, 2006·Thrombosis Research·Derrick L SaulsMaureane Hoffman
Aug 19, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Mark E Molitch
May 27, 2008·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Jean-Claude AnsquerChristelle Foucher
Jun 11, 2009·Current Opinion in Lipidology·Per-Ola Attman, Ola Samuelsson
Aug 1, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Seok Joon ShinCheol Whee Park
Sep 17, 2009·European Journal of Clinical Pharmacology·Jianyong WuJianghua Chen
Nov 27, 2009·Postgraduate Medicine·Veeraish Chauhan, Megha Vaid
Jan 9, 2010·Clinical Journal of the American Society of Nephrology : CJASN·George A Kaysen
Mar 30, 2010·European Journal of Pharmacology·Mandeep Kumar AroraPitchai Balakumar
Oct 28, 2010·Nature Reviews. Nephrology·Tilman B Drüeke, Ziad A Massy
Apr 12, 2011·Thrombosis and Haemostasis·Lina BadimonGemma Vilahur
May 4, 2011·Journal of Pharmaceutical Sciences·Hiroshi WatanabeToru Maruyama
May 18, 2011·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Michel P Hermans
Jul 28, 2011·American Journal of Nephrology·Rigas G Kalaitzidis, Moses S Elisaf
Nov 4, 2011·The Journal of Clinical Endocrinology and Metabolism·S Genuth, F Ismail-Beigi
Jan 24, 2012·Journal of Clinical Lipidology·Rebecca L AttridgeChristopher R Frei
Feb 22, 2012·Nature Reviews. Nephrology·Murray Epstein, Nosratola D Vaziri

❮ Previous
Next ❯

Citations

Mar 14, 2013·European Journal of Clinical Investigation·Michael S KostapanosMoses S Elisaf
Jun 20, 2017·Journal of Comparative Effectiveness Research·Aya M Abdel MagidSamar F Farid

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Software Mentioned

4D
Aurora

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.